The FDA has approved the first mucoadhesive buccal film therapy for the maintenance treatment of opioid dependence, the manufacturer announced on Friday. Bunavail — a combination of buprenorphine and naloxone — should be used along with counseling and psychosocial support.
The manufacturer says that this mode of delivery is more potent and therefore requires half the dose of the currently marketed sublingual formulation (Suboxone). This “may help to reduce the potential for misuse and diversion and potentially lessen the incidence of certain side effects,” the company says.
Leave a Reply
You must be logged in to post a comment.